Pharma Two B gearing up for next step against Parkinson's with fixed-dose drug
This article was originally published in Scrip
Fresh off its positive Phase I results reported last month, Israeli drug maker Pharma Two B said it is gearing up to start a Phase II study of its experimental fixed-dose combination therapy P2B001, which is being tested as a treatment for early-stage Parkinson's disease (scripintelligence, 14 April 2011).
You may also be interested in...
With new funding in hand, Moderna and its infectious disease venture Valera are going full-speed ahead with a Zika vaccine, taking an mRNA approach, which they said could be a more rapid strategy to try to stop the disease.
Allergan CEO Brent Saunders vows not to engage in price gouging and says his firm will limit cost increases to single-digit percentages, occurring only once per year. But it's unclear whether Saunders will stand as a lone wolf in the industry or if others will make similar pledges.
Hillary Clinton's plan to rein in high prices of older medicines, which includes creating a federal panel that has authority to impose fines, may grab headlines, but some analysts think it's unlikely to get very far in a divided Washington.